Business
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 clinical data for LPCN 1154 have been selected for oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held May 26–29, 2026, in Miami, FL.\n \n \n \n \n \n \n \nOral Presentation details Title:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154Presenter:Benjamin Bruno, PhD, Vice President, Clinical Development, LipocineSession:Pharmaceutical Pipeline (Oral Presentation)Date:Tuesday, May 26, 2026Time:3:20 PM ETLocation:Loews Miami Beach Hotel, Miami, FLThe presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).Poster Presentation Date:Wednesday, May 27, 2026Time:11:45 AM – 1:30 PM ETSession:Poster Session 1, Pharmaceutical PipelinePoster number:W98\"We are pleased that our Phase 3 data for LPCN 1154 was selected for an oral presentation at this year's ASCP meeting, a leading forum for clinical psychopharmacology research,\" said Mahesh V. Patel, Ph.D., President and Chief Executive Officer of Lipocine.About LPCN 1154LPCN 1154, oral brexanolone, a non-SSRI, is chemically identical to the endogenous human hormone allopregnanolone. Brexanolone is a positive allosteric modulator of y-aminobutyric acid (GABAA) receptor. LPCN 1154 has the potential for rescue therapy for PPD with acute stabilization of symptoms in hours and no intensive monitoring requirement. LPCN 1154 has demonstrated clinically meaningful improved tolerability including low CNS depressant side effects, without the risks of disassociation or hallucination of psychedelics, thus potentially enabling a safe, at-home intervention, preserving the maternal-infant bond.About LipocineLipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent en...